Generic Orap ( Pimozide )

Order cheap Generic Orap (Pimozide) without dr prescription in the United States

In our USA pharmacy, you can buy Orap without a prescription, with delivery across the USA within 2‑5 days. Discreet and anonymous packaging.
Orap (pimozide) is a first‑generation antipsychotic (diphenylbutylpiperidine) used to suppress severe motor and vocal tics in patients with Tourette syndrome whose symptoms have not responded to standard treatment. Its exact mechanism is not fully understood, but it is thought to work by blocking central dopamine D2 receptors, thereby reducing the abnormal signaling that provokes tics.
Usual adult dose: Therapy must be initiated at a low dose and titrated gradually. The usual starting dose is 1 mg to 2 mg per day in divided doses. The dose may be increased by 1 mg every other day or every few days, depending on response and tolerability, up to a maximum of 10 mg/day or 0.2 mg/kg/day, whichever is lower.
Dosage form: Oral tablet, 2 mg (also available as 1 mg).
Onset of action: Some reduction in tic severity may be noticed within the first week, but the full therapeutic effect may take several weeks to develop.
Duration of action: The elimination half‑life of pimozide is approximately 55 hours, allowing once‑daily maintenance dosing after initial titration, though divided doses are often used initially.
Alcohol consumption must be strictly avoided. Alcohol can worsen central nervous system depression, increase the risk of dangerous cardiac arrhythmias, and exacerbate extrapyramidal side effects.
Most common side effects: sedation, dry mouth, constipation, akathisia (inner restlessness), and extrapyramidal symptoms such as tremor, stiffness, and slow movement.
Would you like to try Orap without a prescription?

General Information about Orap

• INN (International Nonproprietary Name): Pimozide
• Brand names available in the USA: Orap® (Teva Pharmaceuticals USA, Inc.). Generic pimozide tablets are manufactured by several companies, including Teva, Mylan, and Par Pharmaceutical.
• ATC code: N05AG02
• Dosage forms and strengths: Oral tablets: 1 mg and 2 mg.
• Manufacturers in USA: Teva Pharmaceuticals USA, Inc. (brand Orap®); generic manufacturers include Mylan Pharmaceuticals Inc. and Par Pharmaceutical, among other FDA‑approved companies.
• Registration status in USA: Approved by the U.S. Food and Drug Administration (FDA) (NDA 017473).
• OTC / Rx classification: Prescription only (Rx).

Mechanism of Action and Pharmacology

Pimozide is a diphenylbutylpiperidine neuroleptic that primarily acts as a potent antagonist at dopamine D2 receptors in the central nervous system. By blocking these receptors, particularly in the basal ganglia and limbic system, pimozide is thought to reduce the hyperdopaminergic activity implicated in motor tics and vocalizations of Tourette syndrome. It also has some affinity for 5‑HT2 receptors, which may contribute to its clinical effects. Unlike many other antipsychotics, pimozide has minimal antihistaminic or anticholinergic activity, though anticholinergic side effects can still occur. After oral administration, it is slowly and variably absorbed from the gastrointestinal tract; food may enhance absorption, but taking it with a consistent meal is recommended. Peak plasma concentrations occur 6‑8 hours after a dose. The drug is extensively metabolized in the liver, primarily via CYP3A4 and to a lesser extent CYP2D6, and its metabolites are excreted in the urine and feces. The elimination half‑life is prolonged, ranging from 28 to 110 hours (mean approximately 55 hours), which permits once‑daily dosing once the patient is stabilized. Pimozide's long half‑life also means that steady‑state levels are reached slowly, and adverse effects may develop or worsen over weeks.

Indications

• Suppression of motor and phonic tics in patients with Tourette syndrome who have failed to respond satisfactorily to standard treatment. Orap is not indicated as first‑line therapy and should be reserved for patients with severe, intractable symptoms.
• Orap is not approved for use in any other psychiatric condition; its use in psychotic disorders is not recommended due to a higher risk of serious cardiovascular events.

Important Warnings and Precautions

Orap carries a boxed warning for QT prolongation and sudden death. Pimozide can cause a dose‑related prolongation of the QT interval, which may lead to life‑threatening ventricular arrhythmias including torsades de pointes. Therefore, an electrocardiogram (ECG) must be obtained at baseline and periodically during dose adjustment and maintenance. Do not initiate therapy if the baseline QTc interval is >450 msec in males or >470 msec in females. If QTc exceeds these limits during treatment, the dose must be reduced or the drug discontinued. Concomitant use with other drugs that prolong the QT interval, potent CYP3A4 inhibitors, or drugs causing electrolyte disturbances is contraindicated. Pimozide may also cause neuroleptic malignant syndrome (NMS), a potentially fatal condition characterized by hyperthermia, muscle rigidity, autonomic instability, and altered consciousness; discontinue immediately if NMS is suspected. Tardive dyskinesia, a syndrome of involuntary, irreversible movements, can occur with long‑term use; the lowest effective dose and shortest duration are recommended. Extrapyramidal symptoms (parkinsonism, dystonia, akathisia) may appear; dose reduction or antiparkinsonian medication may be necessary. Hyperprolactinemia can cause galactorrhea, gynecomastia, and menstrual irregularities.

At‑risk groups

• Elderly: Elderly patients are more susceptible to QT prolongation, orthostatic hypotension, and anticholinergic effects. Use with caution; start with the lowest possible dose and monitor ECG and electrolytes. Not recommended for dementia‑related behavioral disturbances due to increased mortality risk.
• Pregnancy: There are no adequate studies in pregnant women. Pimozide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Neonates exposed to antipsychotics during the third trimester are at risk for extrapyramidal symptoms and withdrawal.
• Breastfeeding: It is not known whether pimozide is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or the drug.
• Renal impairment: The drug and its metabolites are primarily excreted via the kidney. In patients with significant renal impairment, dose reduction and close monitoring are recommended.
• Hepatic impairment: Contraindicated in patients with clinically significant hepatic impairment due to the risk of reduced clearance and accumulation.
• Pediatric: Pimozide is approved for Tourette syndrome in children 12 years and older. The starting dose in children is 0.5 mg per day, gradually increased. The maximum dose is 0.2 mg/kg/day or 10 mg/day, whichever is less. ECG monitoring is mandatory. Not recommended for children under 12 years.
• Cardiac conditions: Contraindicated in patients with congenital long QT syndrome, a history of cardiac arrhythmias, severe cardiovascular disease, or those with uncorrected electrolyte abnormalities.
• History of seizures: May lower seizure threshold; use with caution in patients with a seizure disorder.

Driving and alcohol

Pimozide can cause sedation, dizziness, and blurred vision, which may impair the ability to drive or operate machinery. Patients should avoid hazardous activities until they are certain the medication does not adversely affect them. Alcohol must be strictly avoided; it can compound CNS depression and may increase the risk of QT prolongation and liver stress.

Dosage Instructions

• Adults and children 12 years and older: Initial dose is 1 mg to 2 mg per day, given as a single dose or divided. The dose may be increased by 1 mg every other day (or every 2‑3 days for slower titration) based on clinical response and ECG findings. The usual maintenance dose is 6 mg per day, divided into two doses. The maximum dose is 10 mg per day or 0.2 mg/kg/day, whichever is less.
• Titration and monitoring: An ECG must be performed at baseline, after every dose increase, and at least annually during maintenance. If the QTc interval is prolonged beyond 450 msec (males) or 470 msec (females), the dose must be reduced or the drug stopped.
• Administration: Tablets may be taken with or without food, but taking with a consistent meal can improve absorption and reduce stomach upset. Swallow the tablet whole with water; do not crush or chew. Once‑daily dosing at bedtime may be used to reduce daytime sedation once the dose is stable.
• Missed dose: If a dose is missed, take it as soon as remembered. If it is almost time for the next dose, skip the missed dose. Do not double the dose.

Side Effects and Contraindications

Most common side effects: Sedation (10‑20%), dry mouth, constipation, akathisia (restlessness), parkinsonian symptoms (tremor, rigidity, bradykinesia), dizziness, and blurred vision. These are dose‑dependent and may be managed with dose reduction or adjunctive medication.
Other adverse reactions: Headache, depression, insomnia, dyskinesia, and galactorrhea due to hyperprolactinemia.
Serious adverse reactions: QT prolongation leading to ventricular arrhythmias and sudden death, neuroleptic malignant syndrome (hyperthermia, muscle rigidity, autonomic instability), tardive dyskinesia (potentially irreversible), seizures, priapism, and agranulocytosis. Tardive dyskinesia may appear after prolonged therapy or even after discontinuation.
Absolute contraindications: Congenital long QT syndrome or a history of cardiac arrhythmias; severe cardiovascular disease; uncorrected hypokalemia or hypomagnesemia; concomitant use with drugs that prolong the QT interval or are potent CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole, ritonavir, nefazodone); known hypersensitivity to pimozide; clinically significant hepatic impairment.

Drug Interactions

• QT‑prolonging agents (e.g., Class IA and III antiarrhythmics, certain antipsychotics, macrolide antibiotics, fluoroquinolones, methadone): Additive risk of dangerous arrhythmias; concomitant use is contraindicated.
• Potent CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, ketoconazole, nefazodone, ritonavir): Significantly increase pimozide levels and the risk of QT prolongation; coadministration is contraindicated.
• Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole, verapamil): May increase pimozide exposure; careful monitoring and dose adjustment are required.
• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, bupropion): Pimozide is partially metabolized by CYP2D6; coadministration may increase levels; use with caution.
• Diuretics and other drugs causing electrolyte disturbances: Hypokalemia or hypomagnesemia increases the risk of QT prolongation; electrolytes must be normalized before starting pimozide and monitored regularly.
• Centrally acting depressants (e.g., alcohol, opioids, benzodiazepines): Additive sedation and respiratory depression; avoid alcohol entirely.
• Grapefruit juice: A moderate CYP3A4 inhibitor; avoid large quantities during treatment.

Practical Advice

• Take Orap exactly as prescribed. Do not change the dose or stop taking it abruptly without consulting your physician, as withdrawal symptoms may occur and tics may rebound.
• Attend all scheduled appointments for ECG monitoring. Inform your doctor immediately if you experience palpitations, fainting, or dizziness, which could indicate a heart rhythm problem.
• Avoid alcohol entirely during treatment; it increases the risk of serious cardiac and neurological side effects.
• Be aware of early signs of neuroleptic malignant syndrome: high fever, severe muscle stiffness, confusion, sweating, or rapid heart rate. Seek emergency medical help if these develop.
• Report any involuntary movements of the tongue, face, mouth, or limbs, as these could be signs of tardive dyskinesia, which may become permanent.
• Do not drive or operate heavy machinery until you know how the medication affects you, as it can cause significant drowsiness.
• Store tablets at room temperature (15‑25°C / 59‑77°F) in a dry place, away from light. Keep out of reach of children.
• Never share your medication with anyone else. Orap is prescribed for your specific condition based on careful medical evaluation and ongoing monitoring.

Alternative Medications

• Haloperidol (Haldol®): Another first‑generation antipsychotic that is effective for Tourette syndrome; more widely used but also carries risks of extrapyramidal symptoms and QT prolongation.
• Aripiprazole (Abilify®): A second‑generation antipsychotic with partial D2 agonism, approved for Tourette syndrome in children and adults; generally better tolerated with a lower risk of movement disorders.
• Risperidone (Risperdal®): A second‑generation antipsychotic that can reduce tics; may cause weight gain and metabolic effects.
• Clonidine (Catapres®) and guanfacine (Intuniv®): Alpha‑2 adrenergic agonists used for Tourette syndrome, especially in children; often considered first‑line therapy before antipsychotics.
• Topiramate (Topamax®): An antiepileptic that has shown some benefit for tics in small studies.
• Behavioral therapy: Comprehensive Behavioral Intervention for Tics (CBIT) is a non‑pharmacologic first‑line treatment recommended by guidelines.

Clinical Efficacy

Pimozide has demonstrated efficacy in reducing tic frequency and severity in patients with Tourette syndrome in multiple controlled trials. In a pivotal study comparing pimozide to placebo, patients treated with pimozide (mean dose approximately 6 mg/day) showed significant reductions in motor and vocal tic counts as assessed by standardized rating scales. Its efficacy appears comparable to haloperidol, with some evidence suggesting slightly better tolerability in terms of fewer parkinsonian symptoms, though the risk of cardiac effects limits its use. Guidelines reserve pimozide as a second‑ or third‑line agent for patients who have not responded to or cannot tolerate alpha‑2 agonists and other antipsychotics. Ongoing monitoring of cardiac safety is mandatory, and its use has declined with the availability of newer atypical antipsychotics that have a more favorable safety profile for most patients.

Important:

Orap (pimozide) is a potent antipsychotic reserved for severe, treatment‑resistant Tourette syndrome. It carries a boxed warning for QT prolongation and sudden death. An ECG must be checked before starting the medication and periodically thereafter. Do not use Orap with other drugs that prolong the QT interval, strong CYP3A4 inhibitors, or if you have low potassium or magnesium levels. Alcohol is strictly contraindicated. This drug can cause life‑threatening neuroleptic malignant syndrome and potentially irreversible tardive dyskinesia. Doses must be titrated slowly, and the maximum dose must not be exceeded. Elderly patients, children, and those with heart, liver, or kidney problems require extreme caution. Pregnant and breastfeeding women should discuss risks with their physician. Seek immediate medical attention if you experience fast or irregular heartbeat, fainting, high fever, severe muscle stiffness, or involuntary movements. Keep out of reach of children and never share this medication. This information is not a substitute for professional medical advice, diagnosis, or treatment.

How to buy Generic Orap no prescription U.S. Online Pharmacy